Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

ed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Arena Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended Year ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (Note)

Revenues

Total revenues $4,569 $4,699 $19,332 $30,569

Expenses

Research and development 40,690 38,095 149,524 103,388

General and administrative 6,923 5,228 26,571 18,466

Amortization of acquired

technology 384 384 1,537 1,537

Total expenses 47,997 43,707 177,632 123,391

Interest and other income, net 3,042 3,119 15,134 6,574

Net loss (40,386) (35,889) (143,166) (86,248)

Dividends on redeemable

convertible preferred stock (540) (520) (2,114) (2,031)

Net loss allocable to common

stockholders $(40,926) $(36,409) $(145,280) $(88,279)

Net loss per share allocable

to common stockholders,

basic and diluted $(0.60) $(0.73) $(2.31) $(1.89)

Shares used in calculating

net loss per share allocable

to common stockholders, basic

and diluted 68,409 50,108 62,783 46,751

Note: The Condensed Consoli
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... Md. , Dec. 17, 2014  United Therapeutics ... senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics announced ... President and Co-Chief Executive Officer and David Zaccardelli ... Officer.  In connection with these promotions, Dr. Rothblatt,s title ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce ... V19 with PVM technology , is now available. ... measurement tool continuously captures high-resolution images under a ... automatically prepares a report pairing the most relevant ... changes. This compelling blend of high resolution images ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... Byetta LAR Will Earn Decision Resources, Clinical Gold ... According to a New Report from Decision ResourcesWALTHAM, ... the world,s leading research and advisory firms for ... indicate that a therapy,s effect on glycosylated hemoglobin ...
... Frost & Sullivan, the Growth Partnership Company, ... Technologies & Life Sciences Awards at a banquet ... Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"We are honored ... and leadership in the healthcare and technology industries," ...
... Leverage WaferGen,s SmartChip Platform to Evaluate Efficacy ... March 24 WaferGen Biosystems, Inc. (OTC ... state-of-the-art genetic analysis systems, and IR BioSciences ... development-stage biotechnology company focused on the research, ...
Cached Biology Technology:Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes 2Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes 3Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences 2Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences 3Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences 4WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research 2WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research 3WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research 4WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research 5WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research 6WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research 7
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 2008, Dr. Kirt Rusenko, Marine Conservationist, and staff from ... two juvenile loggerhead sea turtles raised in captivity into ... loggerheads, dubbed Milton and FeeBee, hatched on Boca Raton,s ... sex ratio study conducted by Dr. Jeanette Wyneken of ...
... RI Emergency medicine physicians and simulation experts ... advanced medical simulation in five manuscripts appearing in ... Medicine (now available online). The articles describe ... technology, offer unique training opportunities for dynamic, complex ...
... warming has an unexpected ally in mushrooms growing in ... northern regions, a new UC Irvine study finds. ... feed on dead plant material dry out and produce ... wetter soil. This came as a surprise to scientists, ...
Cached Biology News:Loggerhead release to provide vital information to scientific community 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 3Dried mushrooms slow climate warming in Northern forests 2
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
... GC content or with significant secondary structure ... when subjected to PCR result in little ... can be increased by the addition of ... is an effective PCR enhancer for GC-rich ...
...
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
Biology Products: